Sources of novel antibiotics-aside the common roads

Applied Microbiology and Biotechnology

Volumn 88, Issue 6, 2010, Pages 1261-1267

  Donadio, Stefano ^a   Maffioli, Sonia ^a   Monciardini, Paolo ^a   Sosio, Margherita ^a   Jabes, Daniela ^a  

^a NAICONS Srl   (Italy)

Author keywords

Antibiotics; Drug resistance; Natural products

Indexed keywords

CLINICAL DEVELOPMENT; CURRENT STATUS; DRUG RESISTANCE; DRUG-RESISTANT PATHOGENS; MECHANISM OF ACTION; MICROBIAL PATHOGENS; NATURAL PRODUCTS; NEW MECHANISMS; NOVEL ANTIBIOTICS; PHARMACEUTICAL COMPANY; RESISTANCE MECHANISMS;

ANTIBIOTICS;

AC 986446; AFN 1252; ANTIBIOTIC AGENT; CYCLOPEPTIDE; DAPTOMYCIN; FRIULIMICIN; LANTIBIOTIC; LIPOPEPTIDE; MANNOPEPTIMYCIN; NAI 107; NAPHTHYRIDINONE; NBV 302; NVB 302; TIACUMICIN B; UNCLASSIFIED DRUG; VANCOMYCIN;

DRUG RESISTANCE; MICROBIAL ACTIVITY; MOLECULAR ANALYSIS; PATHOGENICITY; PHARMACEUTICAL INDUSTRY; PIPELINE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENDOCARDITIS; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; SEPTICEMIA; SHORT SURVEY; STAPHYLOCOCCUS INFECTION; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BACTERIA; BIOLOGICAL PRODUCTS; DRUG DISCOVERY; HUMANS;

EID: 78649327971     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00253-010-2877-8     Document Type: Short Survey

References (56)

1. G Ackermann B Loffler D Adler AC Rodloff 2004 In vitro activity of OPT-80 against Clostridium difficile Antimicrob Agents Chemother 48 2280 2282 1:CAS:528:DC%2BD2cXks1yqurw%3D 10.1128/AAC.48.6.2280-2282.2004 (Pubitemid 38691631)
2. Appleyard AN, Ayala T, Boakes S, Vcortes J, Dawson MG, Choi S, Lightfoot A, Read D, Todd M, Wadman SN (2009) NVB302: a narrow spectrum antibiotic under development for the treatment of Clostridium difficile infection. 49th Intersci Conf on Antimicrob Agents Chemother, San Francisco, Poster F1-1517
3. S Boakes J Cortés AN Appleyard BA Rudd MJ Dawson 2009 Organization of the genes encoding the biosynthesis of actagardine and engineering of a variant generation system Mol Microbiol 72 1126 1136 1:CAS:528: DC%2BD1MXnsVSrsrc%3D 10.1111/j.1365-2958.2009.06708.x
4. S Boakes AN Appleyard J Cortés MJ Dawson 2010 Organization of the biosynthetic genes encoding deoxyactagardine B (DAB), a new lantibiotic produced by Actinoplanes liguriae NCIMB41362 J Antibiot 63 7 351 358 1:CAS:528:DC%2BC3cXpt1Ontbc%3D 10.1038/ja.2010.48
5. E Breukink B de Kruijff 2006 Lipid II as a target for antibiotics Nat Rev Drug Discov 5 321 332 1:CAS:528:DC%2BD28XjtValu7Y%3D 10.1038/nrd2004
6. H Brotz G Bierbaum K Leopold PE Reynolds HG Sahl 1998 The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting Lipid II Antimicrob Agents Chemother 42 154 160 1:CAS:528:DyaK1cXisVOksQ%3D%3D
7. F Castiglione A Lazzarini L Carrano E Corti I Ciciliato L Gastaldo P Candiani D Losi F Marinelli E Selva F Parenti 2008 Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens Chem Biol 15 22 31 1:CAS:528:DC%2BD1cXpt12qsw%3D%3D 10.1016/j.chembiol.2007.11.009
8. C Chatterjee M Paul L Xie WA van der Donk 2005 Biosynthesis and mode of action of lantibiotics Chem Rev 105 633 684 1:CAS:528:DC%2BD2MXhtFSgs7g%3D 10.1021/cr030105v (Pubitemid 40356090)
9. C Coronelli RJ White GC Lancini F Parenti 1975 Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, biological and biochemical characterization J Antibiot 28 253 259 1:CAS:528:DyaE2MXksFKltbc%3D
10. C Coronelli G Tamoni GC Lancini 1976 Gardimycin, a new antibiotic from Actinoplanes. II. Isolation and preliminary characterization J Antibiot 29 507 510 1:CAS:528:DyaE28Xks1WgtL4%3D
11. KL Credito PC Appelbaum 2004 Activity of OPT-80, a novel macrocycle compared with those of eight other agents against selected anaerobic species Antimicrob Agents Chemother 48 4430 4434 1:CAS:528:DC%2BD2cXpvVykt78%3D 10.1128/AAC.48.11.4430-4434.2004 (Pubitemid 39434908)
12. S Donadio S Maffioli P Monciardini M Sosio D Jabes 2010 Antibiotic discovery in the twenty-first century: current trends and future perspectives J Antibiot 63 423 430 1:CAS:528:DC%2BC3cXhtVOnsb%2FJ 10.1038/ja.2010.62
13. SM Finegold D Molitoris ML Vaisanen Y Song C Liu M Bolaños 2004 In vitro activities of OPT-80 and comparator drugs against intestinal bacteria Antimicrob Agents Chemother 48 4898 4902 1:CAS:528:DC%2BD2cXhtVKmt7nK 10.1128/AAC.48.12.4898-4902.2004 (Pubitemid 39577704)
14. A Gravesen K Sørensen FM Aarestrup S Knøchel 2002 Spontaneous nisin-resistant Listeria monocytogenes mutants with increased expression of a putative penicillin-binding protein and their sensitivity to various antibiotics Microb Drug Resist 7 127 135 10.1089/10766290152045002
15. M Gualtieri P Villain-Guillot J Latouche JP Leonetti L Bastide 2006 Mutation in the Bacillus subtilis RNA Polymerase β' Subunit Confers Resistance to Lipiarmycin Antimicrob Agents Chemother 501 401 402 10.1128/AAC.50.1.401-402.2006 (Pubitemid 43042959)
16. M Gualtieri A Tupin K Brodolin JP Leonetti 2009 Frequency and characterisation of spontaneous lipiarmycin-resistant Enterococcus faecalis mutants selected in vitro Int J Antimicrob Agents 34 605 606 1:CAS:528:DC%2BD1MXhtlGhs7nJ 10.1016/j.ijantimicag.2009.07.003
17. H He RT Williamson B Shen EI Graziani HY Yang SM Sakya PJ Petersen GT Carter 2002 Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygroscopicus LL-AC98 J Am Chem Soc 124 9729 9736 1:CAS:528:DC%2BD38XlsFygtL0%3D 10.1021/ja020257s
18. DW Hecht MA Galang SP Sambol JR Osmolski S Johnson DN Gerding 2007 In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004 Antimicrob Agents Chemother 51 2716 2719 1:CAS:528:DC%2BD2sXoslOjtLk%3D 10.1128/AAC.01623-06 (Pubitemid 47206204)
19. JE Hochlowski SJ Swanson LM Ranfranz DN Whittern AM Buko JB McAlpine 1987 Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Isolation and structure determination J Antibiot 40 575 588 1:CAS:528:DyaL2sXksleqsrs%3D
20. D Jabes S Donadio 2010 Strategies for the isolation and characterization of antibacterial lantibiotics Methods Mol Biol 618 31 45 1:CAS:528: DC%2BC3cXhtVSlu73F 10.1007/978-1-60761-594-1-3
21. Jabes D, Brunati C, Guglierame P, Donadio S (2009a) In vitro antibacterial profile of the new lantibiotic NAI-107. 49th Intersci Conf Antimicrob Agents Chemother, San Francisco, Abs F1-1502
22. Jabes D, Candiani G, Romanò G, Brunati C, Riva S (2009b) NAI-107: superior efficacy in animal models of MDR gram positive infections. 49th Intersci Conf Antimicrob Agents Chemother, San Francisco, Poster F1-1503
23. AP Johnson 2007 Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic Curr Opin Investig Drugs 8 168 173 1:CAS:528:DC%2BD2sXjt1SgsLk%3D
24. Kaplan N, Yethon J, Albert M, Bardouniotis E, Thalakada R, Walsh N, Vaughan D, Berman J, Pauls H (2006) In vitro characterization of API-1252, a novel inhibitor of fatty acid biosynthesis, against drug resistant Staphylococci. 46th Intersci Conf on Antimicrob Agents Chemother, San Francisco, Poster F1-0754
25. JA Karlowsky NM Laing T Baudry N Kaplan D Vaughan DJ Hoban GG Zhanel 2007 In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis Antimicrob Agents Chemother 51 1580 1581 1:CAS:528:DC%2BD2sXktlOisrs%3D 10.1128/AAC.01254-06 (Pubitemid 46586859)
26. JA Karlowsky NM Laing GG Zhanel 2008 In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile Antimicrob Agents Chemother 52 4163 4165 1:CAS:528:DC%2BD1cXhtlCgs7bK 10.1128/AAC.00476-08
27. J Kirstein A Hoffmann H Lilie R Schmidt H Rübsamen-Waigmann H Brötz-Oesterhelt A Mogk K Turgay 2009 The antibiotic ADEP reprogrammes ClpP, switching it from a regulated to an uncontrolled protease EMBO Mol Med 1 37 49 1:CAS:528:DC%2BD1MXltVSktbs%3D 10.1002/emmm.200900002
28. FE Koehn 2008 New strategies and methods in the discovery of natural product anti-infective agents: the mannopeptimycins J Med Chem 51 2613 2617 1:CAS:528:DC%2BD1cXktlCiurg%3D 10.1021/jm070432l (Pubitemid 351620781)
29. M Kurabachew SH Lu P Krastel EK Schmitt BL Suresh A Goh JE Knox NL Ma J Jiricek D Beer M Cynamon F Petersen V Dartois T Keller T Dick VK Sambandamurthy 2008 Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis J Antimicrob Chemother 62 713 719 1:CAS:528:DC%2BD1cXhtFCisLjN 10.1093/jac/dkn269
30. Labischinski H, Glenschek-Sieberth M, Endermann R (2007) Friulimicin B shows good efficacy in a staphylococcal murine abscess infection. 47th Intersci Conf Antimicrob Agents Chemother, Chicago, USA, abs F1-1651
31. T Louie M Miller C Donskey K Mullane EJC Goldstein 2009 Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial of patients with Clostridium difficile infection Antimicrob Agents Chemother 53 223 228 1:CAS:528:DC%2BD1MXhs1KksLg%3D 10.1128/AAC.01442-07
32. A Malabarba R Pallanza M Berti B Cavalleri 1990 Synthesis and biological activity of some amide derivatives of the lantibiotic actagardine J Antibiot 43 1089 1097 1:CAS:528:DyaK3MXisVGluw%3D%3D (Pubitemid 20324371)
33. LC McDonald GE Killgore A Thompson RC Owens Jr SV Kazakova SV Sambol S Johnson DN Gerding 2005 An epidemic, toxin gene-variant strain of Clostridium difficile N Engl J Med 353 2433 2441 1:CAS:528:DC%2BD2MXhtlShurvP 10.1056/NEJMoa051590 (Pubitemid 41770164)
34. McGhee C, Bogdanovich T, Credito K, Labischinski H, Appelbaum PC (2007) Activity of friulimicin against glycopeptide and daptomycin non-susceptible S. aureus. Abstr. F1-1648, 47th Intersci Conf Antimicrob Agents Chemother, Chicago, USA
35. KT Nguyen X He DC Alexander C Li JQ Gu C Mascio A Van Praagh L Mortin M Chu JA Silverman P Brian RH Baltz 2010 Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties Antimicrob Agents Chemother 54 1404 1413 1:CAS:528:DC%2BC3cXksFOis7o%3D 10.1128/AAC.01307-09
36. R Novak DM Shlaes 2010 The pleuromutilin antibiotics: a new class for human use Curr Opin Investig Drugs 11 182 191 1:CAS:528:DC%2BC3cXnt1Kgt7Y%3D
37. S Omura N Imamura R Oiwa H Kuga R Iwata R Masuma Y Iwai 1986 Clostomicins, new antibiotics produced by Micromonospora echinospora subsp. armeniaca subsp. nov. I. Production, isolation, and physico-chemical and biological properties J Antibiot 39 1407 1412 1:CAS:528:DyaL2sXivFOmsg%3D%3D (Pubitemid 17173124)
38. DJ Payne WH Miller V Berry J Brosky WJ Burgess E Chen WE DeWolf Jr FAP Jr R Greenwood MS Head DA Heerding CA Janson DD Jaworski PM Keller PJ Manley TD Moore KA Newlander S Pearson BJ Polizzi X Qiu SF Rittenhouse C Slater-Radosti KL Salyers MA Seefeld MG Smyth DT Takata IN Uzinskas K Vaidya NG Wallis SB Winram CC Yuan WF Huffman 2002 Discovery of a novel and potent class of FabI-directed antibacterial agents Antimicrob Agents Chemother 46 3118 3124 1:CAS:528:DC%2BD38XntlOgtbk%3D 10.1128/AAC.46.10.3118-3124.2002
39. PJ Petersen TZ Wang RG Dushin PA Bradford 2004 Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin, and other antimicrobial agents against gram-positive clinical isolates Antimicrob Agents Chemother 48 739 746 1:CAS:528:DC%2BD2cXitVGhsb8%3D 10.1128/AAC.48.3.739-746.2004 (Pubitemid 38280318)
40. Priefert H, Bylund L, Pelzer S, Vente A, Labischinski H (2007) Comparative in vitro activity of the novel Lipopeptide Friulimicin B with Daptomycin; the effect of inoculum, pulmonary surfactant and calcium Abst. F1-1643, 47th Intersci Conf Antimicrob Agents Chemother, Chicago, USA
41. A Ruzin G Singh A Severin Y Yang RG Dushin AG Sutherland A Minnick M Greenstein MK May DM Shlaes PA Bradford 2004 Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteria Antimicrob Agents Chemother 48 728 738 1:CAS:528:DC%2BD2cXitVGhsb4%3D 10.1128/AAC.48.3.728-738.2004 (Pubitemid 38280317)
42. T Schneider K Gries M Josten I Wiedemann S Pelzer H Labischinski HG Sahl 2009 The lipopeptide antibiotic Friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate Antimicrob Agents Chemother 53 1610 1618 1:CAS:528:DC%2BD1MXksFWktr0%3D 10.1128/AAC.01040-08
43. MP Singh PJ Petersen WJ Weiss JE Janso SW Luckman EB Lenoy PA Bradford RT Testa M Greenstein 2003 Mannopeptimycins, new cyclic glycopeptide antibiotics produced by Streptomyces hygroscopicus LL-AC98: antibacterial and mechanistic activities Antimicrob Agents Chemother 47 62 69 1:CAS:528:DC%2BD3sXis12itQ%3D%3D 10.1128/AAC.47.1.62-69.2003 (Pubitemid 36070343)
44. AM Slee MA Wuonola RJ Mcripley I Zajac MJ Zawada PT Bartholomew WA Gregory M Forbes 1987 Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721 Antimicrob Agents Chemother 31 1791 1797 1:CAS:528:DyaL1cXhsFyksg%3D%3D
45. AL Sonenshein HB Alexander DM Rothstein SH Fisher 1977 Lipiarmycin-resistant ribonucleic acid polymerase mutants of Bacillus subtilis J Bacteriol 132 73 79 1:CAS:528:DyaE2sXlvFKqsrc%3D
46. RN Swanson DJ Hardy NL Shipkowitz CW Hanson NC Ramer PB Fernandes JJ Clement 1991 In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile Antimicrob Agents Chemother 35 1108 1111 1:CAS:528:DyaK3MXksVWgtbk%3D
47. H Tanaka Y Iwai R Oiwa S Shinohara S Shimizu T Oka S Omura 1977 Studies on bacterial cell wall inhibitors. II. Inhibition of peptidoglycan synthesis in vivo and in vitro by amphomycin Biochim Biophys Acta 497 633 640 1:CAS:528:DyaE2sXkvFKlu7g%3D (Pubitemid 8104438)
48. U Theuretzbacher 2009 Future antibiotics scenarios: is the tide starting to turn? Int J Antimicrob Agents 34 15 20 1:CAS:528:DC%2BD1MXmsVSiu74%3D 10.1016/j.ijantimicag.2009.02.005
49. A Tupin M Gualtieri J-P Leonetti K Brodolin 2010 The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site EMBO 29 15 2527 2537 1:CAS:528:DC%2BC3cXns1GisLk%3D 10.1038/emboj.2010.135
50. L Vértesy E Ehlers H Kogler M Kurz J Meiwes G Seibert M Vogel P Hammann 2000 Friulimicins: novel lipopeptide antibiotics with peptidoglycan synthesis inhibiting activity from Actinoplanes friuliensis sp. nov. II. Isolation and structural characterization J Antibiot 53 816 827
51. Wadman SN (2009) Lantibiotic-based compounds having antimicrobial activity. WO/2009/010765
52. Wadman SN, Citron DM, Choi S, Cortes J, Goldstein EJC (2009) NVB302: in vitro activity against Clostridium difficile and intestinal strains of anaerobic bacteria. 49th Intersci Conf Antimicrob Agents Chemother, San Francisco, USA, abs F1-1518
53. C Walsh 2003 Where will new antibiotics come from? Nat Rev Microbiol 1 65 70 1:CAS:528:DC%2BD3sXptFWlu7s%3D 10.1038/nrmicro727
54. WJ Weiss T Murphy E Lenoy M Young 2004 In vivo efficacy and pharmacokinetics of AC98-6446, a novel cyclic glycopeptide, in experimental infection models Antimicrob Agents Chemother 48 1708 1712 1:CAS:528: DC%2BD2cXjslClurw%3D 10.1128/AAC.48.5.1708-1712.2004 (Pubitemid 38544378)
55. Weiss WJB, Hafkin B, Kaplan N, Pulse M, Nguyen P (2008) Efficacy of AFN-1252 and vancomycin in the mouse subcutaneous abscess model with a methicillin-resistant S. aureus. 48th Intersci Conf Antimicrob Agents Chemother, Washington, DC, abs F1-329
56. 13C-NMR assignments and revised primary structure Eur J Biochem 228 786 797 1:CAS:528:DyaK2MXksl2qt78%3D 10.1111/j.1432-1033.1995.tb20324.x